These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 8884844)
1. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Raedle J; Oremek G; Welker M; Roth WK; Caspary WF; Zeuzem S Pancreas; 1996 Oct; 13(3):241-6. PubMed ID: 8884844 [TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of autoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma. Raedle J; Oremek G; Truschnowitsch M; Lorenz M; Roth WK; Caspary WF; Zeuzem S Eur J Cancer; 1998 Jul; 34(8):1198-203. PubMed ID: 9849479 [TBL] [Abstract][Full Text] [Related]
3. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Marxsen J; Schmiegel W; Röder C; Harder R; Juhl H; Henne-Bruns D; Kremer B; Kalthoff H Br J Cancer; 1994 Nov; 70(5):1031-4. PubMed ID: 7947080 [TBL] [Abstract][Full Text] [Related]
4. The role of anti-p53-autoantibodies in pancreatic disorders. Gansauge S; Gansauge F; Negri G; Galle P; Müller J; Nüssler AK; Poch B; Beger HG Int J Pancreatol; 1996 Jun; 19(3):171-8. PubMed ID: 8807362 [TBL] [Abstract][Full Text] [Related]
5. Simplified approaches for the development of an ELISA to detect circulating autoantibodies to p53 in cancer patients. Cressey R; Pimpa S; Chewaskulyong B; Lertprasertsuke N; Saeteng S; Tayapiwatana C; Kasinrerk W BMC Biotechnol; 2008 Feb; 8():16. PubMed ID: 18284706 [TBL] [Abstract][Full Text] [Related]
6. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. Laurent-Puig P; Lubin R; Semhoun-Ducloux S; Pelletier G; Fourre C; Ducreux M; Briantais MJ; Buffet C; Soussi T Gut; 1995 Mar; 36(3):455-8. PubMed ID: 7698709 [TBL] [Abstract][Full Text] [Related]
7. Clinical implication of anti-p53 antibodies and p53-protein in pancreatic disease. Ohshio G; Suwa H; Imamura M Int J Gastrointest Cancer; 2002; 31(1-3):129-35. PubMed ID: 12622424 [TBL] [Abstract][Full Text] [Related]
8. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. Suwa H; Ohshio G; Okada N; Wang Z; Fukumoto M; Imamura T; Imamura M Gut; 1997 May; 40(5):647-53. PubMed ID: 9203945 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer. Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480 [TBL] [Abstract][Full Text] [Related]
10. Absence of p53 autoantibodies in sera from glioma patients. Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045 [TBL] [Abstract][Full Text] [Related]
11. Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Raedle J; Roth WK; Oremek G; Caspary WF; Zeuzem S Dig Dis Sci; 1995 Dec; 40(12):2587-94. PubMed ID: 8536517 [TBL] [Abstract][Full Text] [Related]
12. Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer. Li J; Wang LJ; Ying X; Han SX; Bai E; Zhang Y; Zhu Q Scand J Immunol; 2012 Mar; 75(3):342-9. PubMed ID: 22010875 [TBL] [Abstract][Full Text] [Related]
13. Mutant p53 protein in serum could be used as a molecular marker in human breast cancer. Balogh GA; Mailo DA; Corte MM; Roncoroni P; Nardi H; Vincent E; Martinez D; Cafasso ME; Frizza A; Ponce G; Vincent E; Barutta E; Lizarraga P; Lizarraga G; Monti C; Paolillo E; Vincent R; Quatroquio R; Grimi C; Maturi H; Aimale M; Spinsanti C; Montero H; Santiago J; Shulman L; Rivadulla M; Machiavelli M; Salum G; Cuevas MA; Picolini J; Gentili A; Gentili R; Mordoh J Int J Oncol; 2006 Apr; 28(4):995-1002. PubMed ID: 16525651 [TBL] [Abstract][Full Text] [Related]
14. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9. Slesak B; Harlozinska-Szmyrka A; Knast W; Sedlaczek P; van Dalen A; Einarsson R Cancer; 2000 Jul; 89(1):83-8. PubMed ID: 10897004 [TBL] [Abstract][Full Text] [Related]
15. p53 protein expression and CA19.9 values in differential cytological diagnosis of pancreatic cancer complicated with chronic pancreatitis and chronic pancreatitis. Mu DQ; Wang GF; Peng SY World J Gastroenterol; 2003 Aug; 9(8):1815-8. PubMed ID: 12918127 [TBL] [Abstract][Full Text] [Related]
16. Anti-p53 autoantibodies in hepatitis C virus-infected patients. Raedle J; Oremek G; Roth WK; Caspary WF; Zeuzem S Anticancer Res; 1997; 17(4B):3079-81. PubMed ID: 9329606 [TBL] [Abstract][Full Text] [Related]
17. Role of Amylase-α2A Autoantibodies in the Diagnosis of Autoimmune Pancreatitis. Sánchez Castañón M; Zuliani V; Amodio A; Campagnola P; Granato A; Gabbrielli A; Benini L; López Hoyos M; Frulloni L Pancreas; 2015 Oct; 44(7):1078-82. PubMed ID: 26335011 [TBL] [Abstract][Full Text] [Related]
18. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435 [TBL] [Abstract][Full Text] [Related]
19. Autoantibodies to p53 in sera of patients with autoimmune thyroid disease. Fenton CL; Patel A; Tuttle RM; Francis GL Ann Clin Lab Sci; 2000 Apr; 30(2):179-83. PubMed ID: 10807162 [TBL] [Abstract][Full Text] [Related]
20. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients. Shimizu K; Ueda Y; Yamagishi H Gastric Cancer; 2005; 8(4):214-9. PubMed ID: 16328595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]